Analyst Price Target is $5.25
▲ +1,149.70% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Oncorus in the last 3 months. The average price target is $5.25, with a high forecast of $7.00 and a low forecast of $2.00. The average price target represents a 1,149.70% upside from the last price of $0.42.
Current Consensus is
The current consensus among 3 investment analysts is to hold stock in Oncorus. This rating has held steady since March 2022, when it changed from a Buy consensus rating.
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.